生物活性

• 描述Tasquinimod is a novel inhibitor of tumor angiogenesis that enhances the therapeutic anticancer response when combine with other standard-of-care modalities (radiation, androgen ablation, and/or taxan-based chemotherapies) in experimental animal models^[3]. Tasquinimod has been documented to have a robust and consistent anti-angiogenic activity in vitro at dose between 10-50μM and in vivo at 1-10mg/kg/day resulting in a potent anti-tumor effect in rodent and human prostate cancer xenografts tested in the same dose range^[4].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00560482	Prostate Cancer	Phase 2	Completed	-	-
  NCT01743469	Advanced or Metastatic Hepatoc... more >>ellular Cancer Advanced or Metastatic Ovarian Cancer Metastatic Renal Cell Cancer Advanced or Metastatic Gastric Carcinoma Collapse <<	Phase 2	Completed	-	Belgium ... more >> Antwerp University Hospital, Wilrijkstraat 10 Edegem, Belgium, 2650 Ghent University Hospital, 1K12 IE, De Pintelaan 185 Gent, Belgium, 9000 Leuven cancer institute (LKI), Herestraat Leuven, Belgium, 3000 Canada, Ontario Juravinski Cancer Centre, 699 Concession St Hamilton, Ontario, Canada, L8V 5C2 London Health Sciences Center, 790 Commissoners Road East London, Ontario, Canada, N6A 4L6 Sunnybrook, 2075 Bayview Avenue, Suite T2049 Toronto, Ontario, Canada, M4N 3M5 Princess Margaret, 610 University Avenue Toronto, Ontario, Canada, M5G 2M9 France Hospital Beaujon, 100 Blvd du Général Leclerc Clichy, France, 92110 Centre Oscar Lambret, 3 rue Frédéric Combemale Lille cedex, France, 59020 Bureau d'Etudes Cliniques du Centre Léon Bérard, 28, rue Laennec Lyon, France, 69008 Hospital Saint-Antoine, 184 rue du Faubourg St Antoine Paris, France, 75012 Hopital Europeen Georges-Pompidou, AP-HP, 20 Rue Leblanc Paris, France, 75015 Centre Eugene Marquis, Avenue bataille Flandres Dunkerque Rennes cedex, France, 35042 Centre René Gauducheau, Boulevard Jacques Monod Saint Herblain, France, 44805 Institute Gustave-Roussy, 114 rue Edouard Vaillant Villejuif, France, 94805 Spain Hospital del mar, Paseo Maritimo 25-29 Barcelona, Spain, 08003 Hospital Gregorio Marañon, Dr. Esquerdo, 44-46 Madrid, Spain, 28007 MD Anderson Cancer Centre, Ctra. Colmenar Viejo Km. 9 100, Madrid, Spain, 28034 United Kingdom Beatson West of Scotland Cancer Centre, 1053 Great Western Road Glasgow, United Kingdom, G12 0YN Leicester General Hospital, Gwndolen Road Leicester, United Kingdom, LE5 4PW The Royal Marsden Hospital, Downs Rd, Sutton London, United Kingdom, SM2 5PT The Christie Hospital, Wilmslow Road, Withington Manchester, United Kingdom, M20 4BX Freeman Hospital, Freeman Road, High Heaton Newcastle-upon-Tyne, United Kingdom, NE7 7DN Southampton General Hospital, Tremona Road, Shirley Southampton, United Kingdom, SO16 6YD Collapse <<
  NCT02057666	Asian Chemo-naïve Patients Wit... more >>h Metastatic Castrate-resistant Prostate Cancer Collapse <<	Phase 3	Terminated(Development of tasq... more >>uinimod in prostate cancer discontinued) Collapse <<	-	China ... more >> Beijing, China Changsha, China Chengdu, China Chongqing, China Guangzhou, China Hangzhou, China Nanchang, China Nanjing, China Shanghai, China Shantou, China Shenyang, China Soochow, China Tianjin, China Wenzhou, China Wuhan, China Korea, Republic of Cheongju, Korea, Republic of Seoul, Korea, Republic of Taiwan Taichung, Taiwan Taipei, Taiwan Collapse <<

• 更多
• 参考文献

• [1] Isaacs JT, Antony L, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386-99.

  [2] Isaacs JT, Pili R, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006 Dec 1;66(16):1768-78.

  [3] Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs. 2010;19(10):1235-1243.

  [4] Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010;9:107.